fr
Article scientifique
Français

Leucémie lymphoïde chronique : quand débuter le traitement ?

Publié dansRevue médicale suisse, vol. 9, no. 402, p. 1870-1874
Date de publication2013
Résumé

This paper reviews the literature to propose guidelines for managing patients with early-intermediate stage chronic lymphocytic leukemia (CLL). Clinical and biological parameters are sufficient to identify a cohort of patients with high-risk CLL at diagnosis who will have disease progression: anemia (Hb < 100 g/l) or thrombocytopenia (platelets < 100 G/l), bone marrow infiltration (> 30% lymphocytes), a rapid doubling time (less than 6 months) or lymphocytes above 300 g/L, splenomegaly and massive lymphadenopathy, systemic symptoms, uncontrolled autoimmune complications. Patients without those characteristics have low-risk CLL. In the absence of evidence of survival benefit in low-risk CLL, there is no indication for treatment and patients should be followed up by physical examination and complete blood count once or twice a year.

Mots-clés
  • Blood Cell Count/methods
  • Disease Progression
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/pathology/therapy
  • Neoplasm Staging
  • Practice Guidelines as Topic
  • Risk
  • Survival Analysis
  • Time Factors
Citation (format ISO)
BLASER, Samuel, STIRNEMANN, Jérôme, NAGY, Monika. Leucémie lymphoïde chronique : quand débuter le traitement ? In: Revue médicale suisse, 2013, vol. 9, n° 402, p. 1870–1874.
Fichiers principaux (1)
Article (Published version)
accessLevelRestricted
Identifiants
ISSN du journal1660-9379
590vues
1téléchargements

Informations techniques

Création07/11/2015 14:49:00
Première validation07/11/2015 14:49:00
Heure de mise à jour14/03/2023 23:57:12
Changement de statut14/03/2023 23:57:11
Dernière indexation16/01/2024 19:46:55
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack